Development
Recursion Pharmaceuticals, Inc.
RXRX
$5.41
-$0.07-1.28%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -328.07M | -292.56M | -259.99M | -248.82M | -239.48M |
| Total Depreciation and Amortization | 24.40M | 20.06M | 15.47M | 12.72M | 11.76M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 66.14M | 53.64M | 47.34M | 44.19M | 39.28M |
| Change in Net Operating Assets | -50.26M | -39.59M | -42.89M | -42.31M | 104.92M |
| Cash from Operations | -287.78M | -258.45M | -240.07M | -234.23M | -83.52M |
| Capital Expenditure | -11.96M | -17.87M | -25.39M | -37.89M | -37.06M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 1.84M | 1.92M | 1.92M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -117.00K | 233.00K | 61.08M | 82.50M | 230.31M |
| Cash from Investing | -10.23M | -15.72M | 37.61M | 44.61M | 193.25M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -766.00K | -95.00K | -94.00K | -92.00K | -90.00K |
| Issuance of Common Stock | 140.90M | 206.83M | 155.40M | 154.28M | 154.44M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 140.13M | 206.73M | 155.30M | 154.18M | 154.35M |
| Foreign Exchange rate Adjustments | 188.00K | -243.00K | -128.00K | -309.00K | -307.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -157.69M | -67.68M | -47.29M | -35.75M | 263.76M |